ProCE Banner Activity


Acquired Thrombotic Thrombocytopenic Purpura: Clinical Application of Precision Medicine and New Guidelines

Watch this on-demand webcast from a satellite symposia at the 2021 Hematology meeting to learn from the experts the clinical data you need to understand for the accurate diagnosis and management of aTTP, including future directions and key ongoing trials.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: January 26, 2022

Expiration: January 25, 2023

No longer available for credit.



Ara Metjian

Ara Metjian, MD

Associate Professor
Department of Medicine
University of Colorado
Aurora, Colorado

Paul Coppo

Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University
Doctor of Hematology, AP-HP
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from

Sanofi Genzyme

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with aTTP.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate appropriate patients to accurately and promptly differentiate aTTP from other thrombotic microangiopathies using current guidelines, including ADAMTS13 testing and surrogate scoring systems
  • Discuss the rationale for using VWF-targeted therapies as part of the comprehensive management of aTTP
  • Select optimal treatment for patients with newly diagnosed aTTP, including newer therapies in combination with immunosuppression with or without therapeutic plasma exchange
  • Incorporate newer therapies into the management of aTTP based on individual disease characteristics and patient preference
  • Identify patients with aTTP who are eligible for enrollment on a late-phase clinical trial


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Ara Metjian, MD

Associate Professor
Department of Medicine
University of Colorado
Aurora, Colorado

Ara Metjian, MD, has disclosed that he has received consulting fees from Ablynx/Sanofi Aventis, Genentech, and Shire/Takeda and funds for research support from Ablynx/Sanofi Aventis, Genentech, and Shire/Takeda.

Faculty Disclosure

Primary Author

Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University
Doctor of Hematology, AP-HP
Paris, France

Paul Coppo, MD, has disclosed that he has received consulting fees from Alexion Pharmaceuticals, Octapharma AG, Roche, Sanofi, Sanofi Aventis, and Takeda and fees for non-CME/CE services from Alexion Pharmaceuticals, Roche, Sandoz, Sanofi Aventis, and Takeda.

Staff Disclosure


Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, had no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2022, through January 25, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with aTTP.